The deletion of the CDKN2A/ADP-ribosylation factor (ARF) locus, which is observed in approximately 60% of GBM cases, contributes to p53 inactivation by impairing ARF-mediated MDM2 degradation. This evidence concerns the gene MDM2 and glioblastoma.